Biliary Tract Cancer Clinical Trial
Official title:
Multicenter Phase II Study of Docetaxel and Oxaliplatin Combination in Patients With Locally Advanced or Metastatic Biliary Tract Cancer
1. Goals
- The primary goal of this phase II trial is to:
evaluate the response rate of combination chemotherapy with docetaxel and oxaliplatin
in patients with locally advanced or metastatic BTC as first-line therapy
Secondary goals are to:evaluate the treatment-related toxicities of this combination,
investigate progression-free survival (PFS) and overall survival (OS) in this
population
2. Design
The proposed clinical trial is an open label, non-comparative, multicenter phase II trial
according to the two stage testing design by Simon.22
Status | Recruiting |
Enrollment | 53 |
Est. completion date | December 2013 |
Est. primary completion date | December 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Patients who were diagnosed as adenocarcinoma of gallbladder or biliary tract histologically or cytologically 2. Unresectable locally advanced, metastatic, or recurrent biliary tract cancer 3. Patients must be = 18 years old of age 4. ECOG performance status = 2 (see Appendix C) 5. At least one lesion that can be measured by imaging (CT/MRI) according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) (see Appendix D) 6. Estimated life expectancy of more than 3 months 7. Adequate bone marrow function (absolute neutrophil count [ANC] = 1,500/µL, hemoglobin = 9.0 g/dL [correction by transfusion is acceptable], and platelets = 100,000/µL) 8. Adequate kidney function (serum creatinine < 1.5 x upper limit of normal [ULN]) 9. Adequate liver function (serum total bilirubin < 3xULN; serum transaminases levels < 5xUNL) 10. Provision of fully informed consent prior to any study specific procedures Exclusion Criteria: 1. Other tumor type than adenocarcinoma 2. Any previous history of chemotherapy for biliary tract cancer (prior neoadjuvant/adjuvant chemotherapy is allowed, if recurrence occurred more than 6 months after completion of previous chemotherapy) 3. Patients with second primary cancer (except, adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for =5 years) 4. Patients who received radiotherapy on target lesion within 6 months prior to study treatment 5. Patients with defect of central nervous system (CNS) or any psychiatric disorders and CNS metastases 6. Patients who received major surgery within 4 weeks of starting study treatment or was not recovered from any effects of major surgery 7. Pregnant or breastfeeding women and women of childbearing potential not employing adequate contraception 8. Other serious illness or medical conditions A. Clinically significant cardiac disease (uncontrolled congestive heart disease despite treatment [NYHA class III or IV], symptomatic coronary artery disease, unstable angina or myocardial infarction, conduction abnormality like grade 2 AV block, serious arrhythmia needed for medication, uncontrolled hypertension) within 6 months prior to study entry B. Liver cirrhosis (= Child-Pugh class B) C. History of significant neurologic or psychiatric disorders including dementia or seizures D. Active uncontrolled infection E. Other serious underlying medical conditions which could impair the ability of the patient to participate in the study 9. Concomitant administration of any other experimental drug under investigation, or concomitant chemotherapy, hormonal therapy, or immunotherapy |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Eun Ki Song | Chonbuk |
Lead Sponsor | Collaborator |
---|---|
Korean South West Oncology Group |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Response rate | 2years | No | |
Secondary | Treatment-related toxicities | Number and proportion of patients with adverse events according to the NCI-CTCAE (v 4.0) as a measure of treatment-related toxicities | 2 years | Yes |
Secondary | Progression free survival | Both survival curves will be calculated by Kaplan-Meier method and median value will be determined according to the survival curves. The median PFS and OS will be used for measure. |
2 years | Yes |
Secondary | Overall survival | Both survival curves will be calculated by Kaplan-Meier method and median value will be determined according to the survival curves. The median PFS and OS will be used for measure. |
2 years | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Withdrawn |
NCT03110510 -
FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study
|
Phase 2 | |
Completed |
NCT05116891 -
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00380588 -
Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for Patients With Advanced Biliary Tract Cancer
|
Phase 2 | |
Terminated |
NCT00090025 -
XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors
|
Phase 3 | |
Terminated |
NCT04066491 -
Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC
|
Phase 2/Phase 3 | |
Recruiting |
NCT05998447 -
GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer
|
Phase 2 | |
Recruiting |
NCT03718897 -
Identification of Prognostic Gene Mutations in Biliary Tract Cancer Using Whole Genome Sequencing
|
||
Recruiting |
NCT05056116 -
A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer
|
N/A | |
Recruiting |
NCT04692051 -
A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer
|
Phase 2 | |
Terminated |
NCT04057365 -
Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)
|
Phase 2 | |
Recruiting |
NCT04907643 -
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
|
N/A | |
Completed |
NCT02829918 -
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
|
Phase 2 | |
Recruiting |
NCT04584996 -
CIRcular and Non-coding RNAs as Clinically USeful Biomarkers in Pancreaticobiliary Cancers
|
||
Completed |
NCT02579616 -
Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy
|
Phase 2 | |
Recruiting |
NCT05052099 -
Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT01494363 -
Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer
|
Phase 2 | |
Completed |
NCT00753675 -
Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer
|
Phase 2 | |
Terminated |
NCT00630890 -
Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor)
|
Phase 1 | |
Recruiting |
NCT04445532 -
Hepatobiliary Tumors Tissue Samples Acquisition
|